Dravet Syndrome
Biogen and Stoke report positive results for Dravet syndrome drug
July 17, 2025Research and Development Biogen, Dravet Syndrome, Neurology, Stoke Therapeutics, epilepsy, rare diseases
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which is being developed for Dravet …
UCB presents epilepsy research at American Epilepsy Society Annual Meeting
December 9, 2024Research and Development American Epilepsy Society, Dravet Syndrome, Neurology, UCB, sleep
Belgian-based biopharmaceutical company UCB has announced it will present 32 abstracts at the American Epilepsy Society (AES) Annual Meeting – …
FDA refuses to review Zogenix’s Fintepla in Dravet syndrome, shares tumble 30%
April 9, 2019Manufacturing and Production, Sales and Marketing Dravet Syndrome, FDA, Fintepla, Zogenix
California-based biopharma firm Zogenix has been left frustrated after it received a correspondence from the FDA noting its refusal to …
Latest content
Scots neonatal innovations target hearing loss and earlier care
August 28, 2026
Agentis Health Group acquires Clinical Pharmacist Solutions
August 26, 2026
